Minnow Street Minnow Street
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Eli Lilly and Company (LLY)

Healthcare Drug Manufacturers - General
1,148.80 $
-0.5% vs. previous close
Closing price · As of: 31. Jul 2026

Eli Lilly and Company (LLY) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Total Assets" came in at 116,576 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow
Annual Quarterly

All figures in millions of USD.

Balance Sheet LLY
Tick rows to compare them in a chart (up to 4) Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26
54,814 57,916 64,006 63,944 71,875 75,607 78,715 89,389 100,923 114,935 112,476 116,576
21,332 23,007 25,727 25,189 30,204 31,415 32,740 41,261 49,854 62,071 55,629 54,835
2,695 2,381 2,819 2,460 3,224 3,369 3,268 3,093 3,376 9,792 7,163 5,282
2,829 2,494 2,928 2,586 3,364 3,518 3,423 3,221 3,546 9,914 7,268 5,282
9,171 10,364 11,336 10,014 13,079 12,052 13,275 14,003 17,206 19,457 20,155 21,177
4,799 4,901 5,773 6,102 6,482 7,460 7,589 9,311 11,014 12,180 13,744 14,529
11,277 11,863 – – – 16,172 17,102 18,474 20,530 22,316 24,675 –
4,079 4,085 4,940 4,940 5,768 5,768 5,770 5,771 5,771 5,898 5,898 6,130
6,904 6,782 6,907 6,762 6,636 6,537 6,166 6,012 5,908 6,447 6,522 7,374
43,665 46,608 53,143 51,046 58,239 61,286 64,443 73,542 82,574 91,085 85,941 85,378
18,915 21,998 27,293 18,598 27,121 24,674 28,377 30,068 39,020 40,141 35,228 36,634
662 2,245 6,905 1,652 5,162 2,074 5,117 4,016 5,724 1,633 1,635 4,000
2,474 2,435 2,599 2,474 2,925 2,887 3,229 3,442 4,076 4,262 5,379 5,029
18,158 17,924 18,321 24,560 23,730 29,045 28,527 34,500 34,180 40,874 40,868 39,370
11,064 11,220 10,772 12,812 13,562 14,240 14,192 15,765 18,273 23,793 26,535 31,198
10,369 10,310 10,312 12,554 13,178 13,627 13,545 15,100 17,376 22,252 24,470 29,514
949 949 904 904 904 905 903 901 900 899 898 896

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?